A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ, Conrey A, Frey I, Gwaabe E, Menapace LA, Tumburu L, Lundt M, Lequang T, Li Q, Glass K, Dunkelberger EB, Iyer V, Mangus H, Kung C, Dang L, Kosinski PA, Hawkins P, Jeffries N, Eaton WA, Lay Thein S.
Xu JZ, et al. Among authors: mangus h.
Blood. 2022 Nov 10;140(19):2053-2062. doi: 10.1182/blood.2022015403.
Blood. 2022.
PMID: 35576529
Free PMC article.
Clinical Trial.